Anti‐gp210 and anti‐centromere antibodies are different risk factors for the progression of primary biliary cirrhosis

摘要: The predictive role of antinuclear antibodies (ANAs) remains elusive in the long-term outcome primary biliary cirrhosis (PBC). progression PBC was evaluated association with ANAs using stepwise Cox proportional hazard regression and an unconditional logistic model based on data 276 biopsy-proven, definite patients who have been registered to National Hospital Organization Study Group for Liver Disease Japan (NHOSLJ). When death hepatic failure/liver transplantation (LT) defined as end-point, positive anti-gp210 (Hazard ratio (HR) = 6.742, 95% confidence interval (CI): 2.408, 18.877), late stage (Scheuer's 3, 4) (HR 4.285, CI:1.682,10.913) male sex 3.266, CI: 1.321,8.075) were significant risk factors at time initial liver biopsy. clinical failure/LT (i.e., failure type progression) or development esophageal varices hepatocellular carcinoma without developing jaundice (Total bilirubin < 1.5 mg/dL) portal hypertension end-point early 1, 2) patients, a factor [odds (OR) 33.777, 5.930, 636.745], whereas anti-centromere (OR 4.202, 1.307, 14.763). Histologically, most significantly associated more severe interface hepatitis lobular inflammation, anticentromere ductular reaction. Conclusion: These results indicate 2 different types PBC, progression, which may be represented by positive-anti-gp210 positive-anticentromere antibodies, respectively. (HEPATOLOGY 2007;45:118–127.)